Clinical Trials
43 trialsTroFuse-031
Merck Sharp & Dohme LLC
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Bristol-Myers Squibb
Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
g-RAMPP
Martini-Klinik am UKE GmbH
Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
Peking University First Hospital
Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study
Zhongda Hospital
AssiutU
Assiut University
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
MESODEC
University Hospital, Antwerp
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
3 Tesla MRI in Patients With Bladder Cancer
University of Cincinnati
Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W
American University of Beirut Medical Center
HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively:A Perspective Cohort Study
Peking University First Hospital
ROOT
Taproot Health
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
University of California, San Francisco
Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer
OHSU Knight Cancer Institute
Risk-based Screen and Prognostic Analysis for Second Primary Malignancies in Kidney Cancer Patients
Peking University First Hospital
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
A Study of Cadonilimab(AK104)Combined With Standard Treatment for Function Preservation in Urinary System Tumors
Tongji Hospital
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
Instituto do Cancer do Estado de São Paulo
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
The First Affiliated Hospital with Nanjing Medical University
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
FORT-1
Bayer
Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury
Peking Union Medical College Hospital
Outcome of Treating Bladder Cancer in Sohag University Hospital
Sohag University
CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy
CTI BioPharma
Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma
The First Affiliated Hospital with Nanjing Medical University
POUT
Institute of Cancer Research, United Kingdom
A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
Celldex Therapeutics
Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors
University of Maryland, Baltimore
Proton Therapy for High Risk Prostate Cancer
Abramson Cancer Center at Penn Medicine
Effect of Yoga Counselling on Quality of Life and Psychological Outcomes of Prostate Cancer Patients
NMP Medical Research Institute
R115777 in Treating Patients With Advanced Bladder Cancer
National Cancer Institute (NCI)
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy
National Cancer Institute (NCI)
R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Fox Chase Cancer Center
Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy
Sanofi
Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
Ann & Robert H Lurie Children's Hospital of Chicago
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
Cell Genesys
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
Cell Genesys
Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer
VA Office of Research and Development